Sustained response to standard dose osimertinib in a patient with plasma T790M‐positive leptomeningeal metastases from primary lung adenocarcinoma

摘要

Abstract A 44‐year‐old male, never smoker, suffers from stage IV adenocarcinoma of the right lung with epidermal growth factor receptor (EGFR) exon‐21 L858R point mutation on initial presentation. After 23 months of treatment with gefitinib, intercalated with multiple courses of radiotherapy, leptomeningeal metastases (LMs) developed. Acquired T790M mutation was confirmed by the droplet digital polymerase chain reaction plasma EGFR test. After switching to osimertinib at the standard dose, his neurocognitive function improved clinically, coupled with sustained radiological improvement. As this clinical entity is underrepresented in clinical trials, the practicability of plasma EGFR testing and the optimal dose–response relationship of osimertinib in T790M‐positive lung cancer complicated with LM deserves further exploration.